Combined IP Portfolio Offers Attractive Opportunity for Companies Seeking to License Leading Nanowire Technologies

Nanosys Inc. today announced that it has signed two agreements with Harvard University to combine their extensive intellectual property (IP) assets to facilitate out-licensing in two areas: nanowire-based biosensors and nanowire-based non-volatile memories. The IP is available for out-licensing to any interested third parties. The technologies being made available originate from the laboratory of Dr. Charles Lieber (Mark Hymen Professor of Chemistry at Harvard University), as well as many other nanotech researchers at Nanosys and other universities associated with Nanosys. The IP on offer includes Nanosys' extensive portfolio covering all aspects of nanowire production, functionalization, material interface technologies, fabrication technologies, basic devices using nanostructures, applications and architectures, and Harvard's portfolio of nanowire-based biosensor and non-volatile memory related IP.

"The agreements between Nanosys and Harvard reflect an innovative strategy to facilitate the development of two novel disruptive technologies," said Isaac T. Kohlberg, Harvard University's Senior Associate Provost and Chief Technology Development Officer. "We're delighted to be working in concert with Nanosys, a recognized leader in the nanowire space, to identify companies interested in acquiring rights to our innovative nanowire technologies for next-generation biosensors and non-volatile memory."

Andrew Filler, General Counsel and Vice-President of Intellectual Property at Nanosys, commented: "As companies are now realizing the significant commercial value of nanotechnology to expand upon and open up new markets, our goal is to help these companies address these markets using our intellectual property portfolio." He added, "After developing many fundamental technology platforms at Nanosys over the last several years, the company is now focused on commercializing technologies in core business areas including solid state lighting, electronics, energy storage and medical device applications. Our nanotechnology licensing program complements our core business focus, thereby providing the market with a convenient licensing option to our fundamental patent portfolio in areas that we are not fully exploiting ourselves."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Shoei Electronic Materials, Inc. (2019, February 14). Combined IP Portfolio Offers Attractive Opportunity for Companies Seeking to License Leading Nanowire Technologies. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=11097.

  • MLA

    Shoei Electronic Materials, Inc. "Combined IP Portfolio Offers Attractive Opportunity for Companies Seeking to License Leading Nanowire Technologies". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=11097>.

  • Chicago

    Shoei Electronic Materials, Inc. "Combined IP Portfolio Offers Attractive Opportunity for Companies Seeking to License Leading Nanowire Technologies". AZoNano. https://www.azonano.com/news.aspx?newsID=11097. (accessed November 21, 2024).

  • Harvard

    Shoei Electronic Materials, Inc. 2019. Combined IP Portfolio Offers Attractive Opportunity for Companies Seeking to License Leading Nanowire Technologies. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=11097.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.